CA2934462A1 - Compositions and methods of treating ocular diseases - Google Patents
Compositions and methods of treating ocular diseases Download PDFInfo
- Publication number
- CA2934462A1 CA2934462A1 CA2934462A CA2934462A CA2934462A1 CA 2934462 A1 CA2934462 A1 CA 2934462A1 CA 2934462 A CA2934462 A CA 2934462A CA 2934462 A CA2934462 A CA 2934462A CA 2934462 A1 CA2934462 A1 CA 2934462A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- antigen binding
- binding fragment
- subject
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 131
- 208000022873 Ocular disease Diseases 0.000 title claims description 30
- 239000000203 mixture Substances 0.000 title description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 96
- 206010061218 Inflammation Diseases 0.000 claims abstract description 93
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 81
- 230000004761 fibrosis Effects 0.000 claims abstract description 81
- 230000024203 complement activation Effects 0.000 claims abstract description 40
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 27
- 230000000295 complement effect Effects 0.000 claims abstract description 21
- 239000012634 fragment Substances 0.000 claims description 109
- 239000000427 antigen Substances 0.000 claims description 107
- 102000036639 antigens Human genes 0.000 claims description 107
- 108091007433 antigens Proteins 0.000 claims description 107
- 102100022133 Complement C3 Human genes 0.000 claims description 100
- 238000001356 surgical procedure Methods 0.000 claims description 86
- 230000037361 pathway Effects 0.000 claims description 71
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 69
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 69
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 68
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 68
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 68
- 230000004913 activation Effects 0.000 claims description 66
- 206010029113 Neovascularisation Diseases 0.000 claims description 64
- 102100031506 Complement C5 Human genes 0.000 claims description 62
- 108010005642 Properdin Proteins 0.000 claims description 60
- 102100038567 Properdin Human genes 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 56
- 230000015572 biosynthetic process Effects 0.000 claims description 54
- 239000003795 chemical substances by application Substances 0.000 claims description 54
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 49
- 208000032843 Hemorrhage Diseases 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 208000002780 macular degeneration Diseases 0.000 claims description 32
- 230000008397 ocular pathology Effects 0.000 claims description 26
- 208000031472 Retinal fibrosis Diseases 0.000 claims description 24
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 206010046851 Uveitis Diseases 0.000 claims description 21
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 20
- 208000037111 Retinal Hemorrhage Diseases 0.000 claims description 20
- 208000037312 Familial drusen Diseases 0.000 claims description 19
- 208000014674 injury Diseases 0.000 claims description 18
- 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 claims description 17
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 17
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 16
- 230000002207 retinal effect Effects 0.000 claims description 16
- 208000017442 Retinal disease Diseases 0.000 claims description 14
- 206010038923 Retinopathy Diseases 0.000 claims description 14
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 14
- 230000006378 damage Effects 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 12
- 206010003694 Atrophy Diseases 0.000 claims description 11
- 208000002691 Choroiditis Diseases 0.000 claims description 11
- 208000003971 Posterior uveitis Diseases 0.000 claims description 11
- 208000022758 Sorsby fundus dystrophy Diseases 0.000 claims description 11
- 230000037444 atrophy Effects 0.000 claims description 11
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 11
- 210000001525 retina Anatomy 0.000 claims description 11
- 206010065630 Iris neovascularisation Diseases 0.000 claims description 10
- 230000030833 cell death Effects 0.000 claims description 10
- 239000012636 effector Substances 0.000 claims description 10
- 201000008979 rubeosis iridis Diseases 0.000 claims description 10
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 9
- -1 SIRNA-027 Chemical compound 0.000 claims description 9
- 230000007850 degeneration Effects 0.000 claims description 9
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 201000001948 hypertensive retinopathy Diseases 0.000 claims description 8
- 229960003876 ranibizumab Drugs 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000016113 North Carolina macular dystrophy Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000001344 Macular Edema Diseases 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 230000008728 vascular permeability Effects 0.000 claims description 5
- 206010025415 Macular oedema Diseases 0.000 claims description 4
- 206010038848 Retinal detachment Diseases 0.000 claims description 4
- 201000010230 macular retinal edema Diseases 0.000 claims description 4
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 4
- 230000037390 scarring Effects 0.000 claims description 4
- 201000002563 Histoplasmosis Diseases 0.000 claims description 3
- 108091008695 photoreceptors Proteins 0.000 claims description 3
- 206010025421 Macule Diseases 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims 8
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims 4
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 4
- 230000004887 epithelial permeability Effects 0.000 claims 4
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 3
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 3
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 3
- 229940126864 fibroblast growth factor Drugs 0.000 claims 3
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 201000006754 cone-rod dystrophy Diseases 0.000 claims 2
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims 1
- NEZONWMXZKDMKF-JTQLQIEISA-N Alkannin Chemical compound C1=CC(O)=C2C(=O)C([C@@H](O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-JTQLQIEISA-N 0.000 claims 1
- 108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 208000005598 Angioid Streaks Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 claims 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 claims 1
- 208000033825 Chorioretinal atrophy Diseases 0.000 claims 1
- 206010008790 Choroidal rupture Diseases 0.000 claims 1
- 208000021089 Coats disease Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 claims 1
- BGXFQDFSVDZUIW-UHFFFAOYSA-N Decursinol Natural products O1C(=O)C=CC2=C1C=C1OC(C)(C)C(O)CC1=C2 BGXFQDFSVDZUIW-UHFFFAOYSA-N 0.000 claims 1
- 101000743846 Diplobatis ommata Ras-related protein Rab-10 Proteins 0.000 claims 1
- 206010015901 Exudative retinopathy Diseases 0.000 claims 1
- 208000020564 Eye injury Diseases 0.000 claims 1
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 claims 1
- WDXRGPWQVHZTQJ-AUKWTSKRSA-N Guggulsterone Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=O)/C(=C/C)[C@@]1(C)CC2 WDXRGPWQVHZTQJ-AUKWTSKRSA-N 0.000 claims 1
- WDXRGPWQVHZTQJ-NRJJLHBYSA-N Guggulsterone E Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=O)C(=CC)[C@@]1(C)CC2 WDXRGPWQVHZTQJ-NRJJLHBYSA-N 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 1
- 206010059239 Leukaemic retinopathy Diseases 0.000 claims 1
- 241001071917 Lithospermum Species 0.000 claims 1
- 208000031471 Macular fibrosis Diseases 0.000 claims 1
- 208000009857 Microaneurysm Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 206010073286 Pathologic myopia Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010063381 Polypoidal choroidal vasculopathy Diseases 0.000 claims 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 206010038899 Retinal telangiectasia Diseases 0.000 claims 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 claims 1
- MXANJRGHSFELEJ-MRXNPFEDSA-N [(1r)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 3-hydroxy-3-methylbutanoate Chemical compound C1=CC(O)=C2C(=O)C([C@H](OC(=O)CC(C)(C)O)CC=C(C)C)=CC(=O)C2=C1O MXANJRGHSFELEJ-MRXNPFEDSA-N 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 229960002833 aflibercept Drugs 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- UNNKKUDWEASWDN-UHFFFAOYSA-N alkannin Natural products CC(=CCC(O)c1cc(O)c2C(=O)C=CC(=O)c2c1O)C UNNKKUDWEASWDN-UHFFFAOYSA-N 0.000 claims 1
- 208000000252 angiomatosis Diseases 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- MXANJRGHSFELEJ-UHFFFAOYSA-N beta:-hydroxy isovaleryl shikonin Natural products C1=CC(O)=C2C(=O)C(C(OC(=O)CC(C)(C)O)CC=C(C)C)=CC(=O)C2=C1O MXANJRGHSFELEJ-UHFFFAOYSA-N 0.000 claims 1
- PRYZSLKPMFOUNL-MHIBGBBJSA-N bevasiranib Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C(NC(=O)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 PRYZSLKPMFOUNL-MHIBGBBJSA-N 0.000 claims 1
- 229950006615 bevasiranib Drugs 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 claims 1
- BGXFQDFSVDZUIW-LBPRGKRZSA-N decursinol Chemical compound O1C(=O)C=CC2=C1C=C1OC(C)(C)[C@@H](O)CC1=C2 BGXFQDFSVDZUIW-LBPRGKRZSA-N 0.000 claims 1
- 208000001309 degenerative myopia Diseases 0.000 claims 1
- 230000004340 degenerative myopia Effects 0.000 claims 1
- 150000002066 eicosanoids Chemical class 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 claims 1
- 230000007277 glial cell activation Effects 0.000 claims 1
- 229950000700 guggulsterone Drugs 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- IXAQOQZEOGMIQS-SSQFXEBMSA-N lipoxin A4 Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC(O)=O IXAQOQZEOGMIQS-SSQFXEBMSA-N 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 1
- 229960003407 pegaptanib Drugs 0.000 claims 1
- 210000003668 pericyte Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- YJGVMLPVUAXIQN-HAEOHBJNSA-N picropodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-HAEOHBJNSA-N 0.000 claims 1
- 201000009015 preretinal fibrosis Diseases 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims 1
- 208000019793 rhegmatogenous retinal detachment Diseases 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- WDXRGPWQVHZTQJ-UHFFFAOYSA-N trans-guggulsterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CC(=O)C(=CC)C1(C)CC2 WDXRGPWQVHZTQJ-UHFFFAOYSA-N 0.000 claims 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 1
- 229950000578 vatalanib Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 abstract description 37
- 230000001575 pathological effect Effects 0.000 abstract description 10
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 88
- 238000001994 activation Methods 0.000 description 55
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 description 53
- 238000005755 formation reaction Methods 0.000 description 51
- 230000002757 inflammatory effect Effects 0.000 description 44
- 238000004519 manufacturing process Methods 0.000 description 33
- 230000007170 pathology Effects 0.000 description 31
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 28
- 102000004127 Cytokines Human genes 0.000 description 25
- 108090000695 Cytokines Proteins 0.000 description 25
- 239000003102 growth factor Substances 0.000 description 22
- 201000004569 Blindness Diseases 0.000 description 21
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 21
- 206010030113 Oedema Diseases 0.000 description 20
- 230000004393 visual impairment Effects 0.000 description 19
- 230000002792 vascular Effects 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 230000017423 tissue regeneration Effects 0.000 description 17
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 230000029663 wound healing Effects 0.000 description 16
- 108090000056 Complement factor B Proteins 0.000 description 15
- 102000003712 Complement factor B Human genes 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 13
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 13
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 208000037816 tissue injury Diseases 0.000 description 13
- 208000010412 Glaucoma Diseases 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 208000023275 Autoimmune disease Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 208000025531 adult-onset foveomacular vitelliform dystrophy Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 210000000987 immune system Anatomy 0.000 description 11
- 201000003142 neovascular glaucoma Diseases 0.000 description 11
- 230000002980 postoperative effect Effects 0.000 description 11
- 230000008733 trauma Effects 0.000 description 11
- 208000021331 vascular occlusion disease Diseases 0.000 description 11
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 10
- 208000027073 Stargardt disease Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 230000008482 dysregulation Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229940076783 lucentis Drugs 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 9
- 201000001320 Atherosclerosis Diseases 0.000 description 9
- 241000282560 Macaca mulatta Species 0.000 description 9
- 201000007527 Retinal artery occlusion Diseases 0.000 description 9
- 206010053648 Vascular occlusion Diseases 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 9
- 230000004154 complement system Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
- 230000021917 activation of membrane attack complex Effects 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 201000004982 autoimmune uveitis Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 231100000241 scar Toxicity 0.000 description 7
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 6
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 6
- 208000019878 Eales disease Diseases 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 230000006037 cell lysis Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 108010089414 Anaphylatoxins Proteins 0.000 description 5
- 208000009137 Behcet syndrome Diseases 0.000 description 5
- 208000031969 Eye Hemorrhage Diseases 0.000 description 5
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 206010022941 Iridocyclitis Diseases 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 description 5
- 208000004788 Pars Planitis Diseases 0.000 description 5
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 5
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 5
- 206010039705 Scleritis Diseases 0.000 description 5
- 241000282485 Vulpes vulpes Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 201000004612 anterior uveitis Diseases 0.000 description 5
- 201000004709 chorioretinitis Diseases 0.000 description 5
- 230000006020 chronic inflammation Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 201000004180 corneal endothelial dystrophy Diseases 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 201000006902 exudative vitreoretinopathy Diseases 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 201000004614 iritis Diseases 0.000 description 5
- 208000018769 loss of vision Diseases 0.000 description 5
- 231100000864 loss of vision Toxicity 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 101100481754 Rattus norvegicus Lta gene Proteins 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000004155 blood-retinal barrier Anatomy 0.000 description 4
- 230000004378 blood-retinal barrier Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000009795 derivation Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 108010032674 lampalizumab Proteins 0.000 description 4
- 229950000482 lampalizumab Drugs 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000006711 vascular endothelial growth factor production Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- REAQAWSENITKJL-DDWPSWQVSA-N Ala-Met-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O REAQAWSENITKJL-DDWPSWQVSA-N 0.000 description 3
- 101150073986 C3AR1 gene Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 101000795624 Homo sapiens Pre-rRNA-processing protein TSR1 homolog Proteins 0.000 description 3
- 101000741544 Homo sapiens Properdin Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102100031564 Pre-rRNA-processing protein TSR1 homolog Human genes 0.000 description 3
- 208000021016 Retinal Arterial Macroaneurysm Diseases 0.000 description 3
- 101100378956 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AMD2 gene Proteins 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 210000001775 bruch membrane Anatomy 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 230000001497 fibrovascular Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 201000004849 posterior scleritis Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 208000032253 retinal ischemia Diseases 0.000 description 3
- 230000004233 retinal vasculature Effects 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 230000008354 tissue degradation Effects 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 description 2
- 206010015871 Extravascular haemolysis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 208000035965 Postoperative Complications Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 201000001949 Retinal Vasculitis Diseases 0.000 description 2
- 102100039270 Ribulose-phosphate 3-epimerase Human genes 0.000 description 2
- 101100154704 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TSR4 gene Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 208000027276 Von Willebrand disease Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000007917 background diabetic retinopathy Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 229940082707 skyla Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 210000002301 subretinal fluid Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000004222 uncontrolled growth Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000006444 vascular growth Effects 0.000 description 2
- 230000006439 vascular pathology Effects 0.000 description 2
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 2
- AMRUKLMZDPPJNU-IOLLQWDPSA-N (2-hydroxy-3-octadecanoyloxypropyl) (5e,8e,11e,14e)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCC\C=C\C\C=C\C\C=C\C\C=C\CCCCC AMRUKLMZDPPJNU-IOLLQWDPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 1
- 102100031548 18S rRNA aminocarboxypropyltransferase Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000003706 Complement factor D Human genes 0.000 description 1
- 108090000059 Complement factor D Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 206010011033 Corneal oedema Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 208000016974 Eales' disease Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101000795618 Homo sapiens 18S rRNA aminocarboxypropyltransferase Proteins 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000795631 Homo sapiens Pre-rRNA-processing protein TSR2 homolog Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057267 Periphlebitis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100031557 Pre-rRNA-processing protein TSR2 homolog Human genes 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 108010092377 aminoalcoholphosphotransferase Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 235000019993 champagne Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000004778 corneal edema Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 101150031187 fba gene Proteins 0.000 description 1
- 238000013534 fluorescein angiography Methods 0.000 description 1
- 201000006321 fundus dystrophy Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- BWJYPABMMFBINC-UHFFFAOYSA-N n-[2-(4-azido-3-iodophenyl)ethyl]-4-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]pentanamide Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNC(C)CCC(=O)NCCC1=CC=C(N=[N+]=[N-])C(I)=C1 BWJYPABMMFBINC-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 101150066142 tsr gene Proteins 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920541P | 2013-12-24 | 2013-12-24 | |
| US61/920,541 | 2013-12-24 | ||
| PCT/US2014/049938 WO2015099838A2 (en) | 2013-12-24 | 2014-08-06 | Compositions and methods of treating ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2934462A1 true CA2934462A1 (en) | 2015-07-02 |
Family
ID=53479755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2934462A Abandoned CA2934462A1 (en) | 2013-12-24 | 2014-08-06 | Compositions and methods of treating ocular diseases |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10183989B2 (enExample) |
| EP (1) | EP3086809A4 (enExample) |
| JP (1) | JP2017502023A (enExample) |
| AU (1) | AU2014370404A1 (enExample) |
| CA (1) | CA2934462A1 (enExample) |
| WO (1) | WO2015099838A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| IL261188B (en) | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| WO2019033081A1 (en) * | 2017-08-11 | 2019-02-14 | Massachusetts Eye And Ear Infirmary | INHIBITION OF THE SUPPLEMENTARY ALTERNA PATHWAY FOR THE TREATMENT OF RETINAL ISCHEMIC LESION AND GLAUCOMA |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| BR112020019907A2 (pt) | 2018-04-03 | 2021-01-05 | Ngm Biopharmaceuticals, Inc. | Agentes de ligação a c3 e métodos de uso dos mesmos |
| EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| CN109999015A (zh) * | 2019-04-24 | 2019-07-12 | 江苏省中医药研究院 | 紫草素在制备预防或治疗房颤药物中的用途 |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| IL301762A (en) * | 2020-10-07 | 2023-05-01 | Line 6 Biotechnology Inc | Methods and materials for the treatment of eye diseases |
| US11981727B2 (en) | 2021-08-31 | 2024-05-14 | Novelmed Therapeutics, Inc | Monospecific and bispecific antibodies and antigen binding fragments thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030171320A1 (en) * | 2001-11-09 | 2003-09-11 | Guyer David R. | Methods for treating ocular neovascular diseases |
| DK1931379T3 (da) * | 2005-10-07 | 2013-08-19 | Sec Dep For Health | Proteiner med forbedret opløselighed samt fremgangsmåder til frembringelse og anvendelse af samme |
| ES2551202T5 (es) | 2005-11-04 | 2018-11-30 | Genentech, Inc. | Uso de inhibidores de la vía del complemento para tratar enfermedades oculares |
| HUE026496T2 (en) | 2006-03-08 | 2016-06-28 | Archemix Llc | Complement-binding aptamers and anti-C5 agents for treating eye diseases |
| WO2011112850A2 (en) | 2010-03-10 | 2011-09-15 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-properdin antibodies |
| US9745367B2 (en) * | 2007-03-23 | 2017-08-29 | Novelmed Theraputics, Inc. | Alternative pathway specific antibodies for treating arthritis |
| US20100015139A1 (en) | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
| AU2008262048B2 (en) * | 2007-06-07 | 2013-09-26 | Genentech, Inc. | C3b antibodies and methods for the prevention and treatment of complement- associated disorders |
| US20100291106A1 (en) | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| US20190202898A9 (en) * | 2012-04-03 | 2019-07-04 | Novelmed Therapeutics, Inc. | AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF |
| EP2834271B1 (en) | 2012-04-03 | 2019-01-16 | NovelMed Therapeutics, Inc. | Humanized and chimeric anti-factor bb antibodies and uses thereof |
| CN104220453B (zh) * | 2012-04-03 | 2018-03-09 | 诺沃姆德治疗公司 | 人源化的嵌合抗因子c3抗体及其用途 |
-
2014
- 2014-08-06 US US15/106,017 patent/US10183989B2/en active Active
- 2014-08-06 CA CA2934462A patent/CA2934462A1/en not_active Abandoned
- 2014-08-06 WO PCT/US2014/049938 patent/WO2015099838A2/en not_active Ceased
- 2014-08-06 AU AU2014370404A patent/AU2014370404A1/en not_active Abandoned
- 2014-08-06 EP EP14874978.1A patent/EP3086809A4/en not_active Withdrawn
- 2014-08-06 JP JP2016540993A patent/JP2017502023A/ja active Pending
-
2019
- 2019-01-22 US US16/254,173 patent/US10696740B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014370404A1 (en) | 2016-07-07 |
| US20190169279A1 (en) | 2019-06-06 |
| JP2017502023A (ja) | 2017-01-19 |
| US10183989B2 (en) | 2019-01-22 |
| WO2015099838A3 (en) | 2015-10-29 |
| EP3086809A4 (en) | 2017-11-29 |
| US20160319002A1 (en) | 2016-11-03 |
| US10696740B2 (en) | 2020-06-30 |
| EP3086809A2 (en) | 2016-11-02 |
| WO2015099838A2 (en) | 2015-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10696740B2 (en) | Methods of treating ocular diseases | |
| JP6462750B2 (ja) | 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用 | |
| TWI449535B (zh) | 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途 | |
| JP7107914B2 (ja) | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 | |
| IL240898A (en) | Antibodies against a5c for the preparation of drugs for the treatment of related diseases cause an increase | |
| MX2014004449A (es) | Tratamiento de enfermedad ocular. | |
| CA2700481A1 (en) | Antigen binding proteins | |
| KR20200138290A (ko) | C3-결합제 및 이의 사용 방법 | |
| CN113166237A (zh) | 抗fam19a5抗体的用途 | |
| US20180371082A1 (en) | Novel antibody useful in neurological or neurodegenerative disorders | |
| KR20220007128A (ko) | 항-ｓｅｍａ３ａ 항체 및 눈 또는 안구 질환 치료를 위한 이의 용도 | |
| KR20230146053A (ko) | 보체 c3 항원 결합 단백질 | |
| TW202246351A (zh) | Htra1結合劑及其使用方法 | |
| CN110381999B (zh) | 结合人cd160的化合物及其用途 | |
| AU2021304993B2 (en) | Fusion protein including complement pathway inhibitor and angiogenesis inhibitor and use thereof | |
| JP2025519612A (ja) | Ｉｇｆ１ｒ抗体 | |
| CN114423788B (zh) | 抗nrp1a抗体及其用于治疗眼或眼部疾病的用途 | |
| RU2802307C2 (ru) | C3-связывающие агенты и способы их применения | |
| EA049293B1 (ru) | АНТИ-Nrp1A АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗ ИЛИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ | |
| TW202530256A (zh) | 多特異性抗原結合多肽之組合物及使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20200831 |